SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA

Core Viewpoint - Liquidia Corporation is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop after the announcement of tentative FDA approval for its product YUTREPIA™ [1][2]. Group 1: Company Developments - On August 19, 2024, Liquidia announced that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2]. - The company must wait for the expiration of regulatory exclusivity of a competing product before final approval can be granted [2]. Group 2: Market Reaction - Following the FDA announcement, Liquidia's stock price fell by $4.32 per share, representing a decline of 30.62%, closing at $9.79 per share on August 19, 2024 [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Liquidia and its officers and/or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions of dollars in damages for class members over its 85-year history [3].